Literature DB >> 28739891

BACE inhibition-dependent repair of Alzheimer's pathophysiology.

Aylin D Keskin1, Maja Kekuš1, Helmuth Adelsberger1, Ulf Neumann2, Derya R Shimshek2, Beomjong Song1, Benedikt Zott1, Tingying Peng3, Hans Förstl4, Matthias Staufenbiel5, Israel Nelken6, Bert Sakmann7, Arthur Konnerth7,8, Marc Aurel Busche1,4,8.   

Abstract

Amyloid-β (Aβ) is thought to play an essential pathogenic role in Alzheimer´s disease (AD). A key enzyme involved in the generation of Aβ is the β-secretase BACE, for which powerful inhibitors have been developed and are currently in use in human clinical trials. However, although BACE inhibition can reduce cerebral Aβ levels, whether it also can ameliorate neural circuit and memory impairments remains unclear. Using histochemistry, in vivo Ca2+ imaging, and behavioral analyses in a mouse model of AD, we demonstrate that along with reducing prefibrillary Aβ surrounding plaques, the inhibition of BACE activity can rescue neuronal hyperactivity, impaired long-range circuit function, and memory defects. The functional neuronal impairments reappeared after infusion of soluble Aβ, mechanistically linking Aβ pathology to neuronal and cognitive dysfunction. These data highlight the potential benefits of BACE inhibition for the effective treatment of a wide range of AD-like pathophysiological and cognitive impairments.

Entities:  

Keywords:  Alzheimer’s disease; BACE inhibition; amyloid-β; in vivo calcium imaging; neural circuit dysfunction

Mesh:

Substances:

Year:  2017        PMID: 28739891      PMCID: PMC5559049          DOI: 10.1073/pnas.1708106114

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  42 in total

1.  Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques.

Authors:  Robert M Koffie; Melanie Meyer-Luehmann; Tadafumi Hashimoto; Kenneth W Adams; Matthew L Mielke; Monica Garcia-Alloza; Kristina D Micheva; Stephen J Smith; M Leo Kim; Virginia M Lee; Bradley T Hyman; Tara L Spires-Jones
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-19       Impact factor: 11.205

2.  Chronic optogenetic activation augments aβ pathology in a mouse model of Alzheimer disease.

Authors:  Kaoru Yamamoto; Zen-Ichi Tanei; Tadafumi Hashimoto; Tomoko Wakabayashi; Hiroyuki Okuno; Yasushi Naka; Ofer Yizhar; Lief E Fenno; Masashi Fukayama; Haruhiko Bito; John R Cirrito; David M Holtzman; Karl Deisseroth; Takeshi Iwatsubo
Journal:  Cell Rep       Date:  2015-04-30       Impact factor: 9.423

3.  A mutation in APP protects against Alzheimer's disease and age-related cognitive decline.

Authors:  Thorlakur Jonsson; Jasvinder K Atwal; Stacy Steinberg; Jon Snaedal; Palmi V Jonsson; Sigurbjorn Bjornsson; Hreinn Stefansson; Patrick Sulem; Daniel Gudbjartsson; Janice Maloney; Kwame Hoyte; Amy Gustafson; Yichin Liu; Yanmei Lu; Tushar Bhangale; Robert R Graham; Johanna Huttenlocher; Gyda Bjornsdottir; Ole A Andreassen; Erik G Jönsson; Aarno Palotie; Timothy W Behrens; Olafur T Magnusson; Augustine Kong; Unnur Thorsteinsdottir; Ryan J Watts; Kari Stefansson
Journal:  Nature       Date:  2012-08-02       Impact factor: 49.962

4.  Large Soluble Oligomers of Amyloid β-Protein from Alzheimer Brain Are Far Less Neuroactive Than the Smaller Oligomers to Which They Dissociate.

Authors:  Ting Yang; Shaomin Li; Huixin Xu; Dominic M Walsh; Dennis J Selkoe
Journal:  J Neurosci       Date:  2017-01-04       Impact factor: 6.167

5.  Reduced effectiveness of Abeta1-42 immunization in APP transgenic mice with significant amyloid deposition.

Authors:  P Das; M P Murphy; L H Younkin; S G Younkin; T E Golde
Journal:  Neurobiol Aging       Date:  2001 Sep-Oct       Impact factor: 4.673

Review 6.  Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer's disease pathogenesis.

Authors:  Delphine Boche; Nathan Denham; Clive Holmes; James A R Nicoll
Journal:  Acta Neuropathol       Date:  2010-07-15       Impact factor: 17.088

7.  Rescue of long-range circuit dysfunction in Alzheimer's disease models.

Authors:  Marc Aurel Busche; Maja Kekuš; Helmuth Adelsberger; Takahiro Noda; Hans Förstl; Israel Nelken; Arthur Konnerth
Journal:  Nat Neurosci       Date:  2015-10-12       Impact factor: 24.884

Review 8.  Astrocytes in physiological aging and Alzheimer's disease.

Authors:  J J Rodríguez-Arellano; V Parpura; R Zorec; A Verkhratsky
Journal:  Neuroscience       Date:  2015-01-14       Impact factor: 3.590

9.  Staged decline of neuronal function in vivo in an animal model of Alzheimer's disease.

Authors:  Christine Grienberger; Nathalie L Rochefort; Helmuth Adelsberger; Horst A Henning; Daniel N Hill; Julia Reichwald; Matthias Staufenbiel; Arthur Konnerth
Journal:  Nat Commun       Date:  2012-04-10       Impact factor: 14.919

Review 10.  The amyloid hypothesis of Alzheimer's disease at 25 years.

Authors:  Dennis J Selkoe; John Hardy
Journal:  EMBO Mol Med       Date:  2016-06-01       Impact factor: 12.137

View more
  38 in total

1.  Alzheimer's Disease is Driven by Intraneuronally Retained Beta-Amyloid Produced in the AD-Specific, βAPP-Independent Pathway: Current Perspective and Experimental Models for Tomorrow.

Authors:  Vladimir Volloch; Bjorn Olsen; Sophia Rits
Journal:  Ann Integr Mol Med       Date:  2020

2.  Precursor-Independent Overproduction of Beta-Amyloid in AD: Mitochondrial Dysfunction as Possible Initiator of Asymmetric RNA-Dependent βAPP mRNA Amplification. An Engine that Drives Alzheimer's Disease.

Authors:  Vladimir Volloch; Bjorn R Olsen; Sophia Rits
Journal:  Ann Integr Mol Med       Date:  2019-11-20

3.  β-Secretase BACE1 Promotes Surface Expression and Function of Kv3.4 at Hippocampal Mossy Fiber Synapses.

Authors:  Stephanie Hartmann; Fang Zheng; Michele C Kyncl; Sandra Karch; Kerstin Voelkl; Benedikt Zott; Carla D'Avanzo; Selene Lomoio; Giuseppina Tesco; Doo Y Kim; Christian Alzheimer; Tobias Huth
Journal:  J Neurosci       Date:  2018-03-05       Impact factor: 6.167

4.  Protein-Encoding RNA to RNA Information Transfer in Mammalian Cells: RNA-dependent mRNA Amplification. Identification of Chimeric RNA Intermediates and Putative RNA End Products.

Authors:  Sophia Rits; Bjorn R Olsen; Vladimir Volloch
Journal:  Ann Integr Mol Med       Date:  2019-08-22

Review 5.  The β-secretase (BACE) inhibitor NB-360 in preclinical models: From amyloid-β reduction to downstream disease-relevant effects.

Authors:  Ulf Neumann; Rainer Machauer; Derya R Shimshek
Journal:  Br J Pharmacol       Date:  2019-03-10       Impact factor: 8.739

Review 6.  What Happens with the Circuit in Alzheimer's Disease in Mice and Humans?

Authors:  Benedikt Zott; Marc Aurel Busche; Reisa A Sperling; Arthur Konnerth
Journal:  Annu Rev Neurosci       Date:  2018-07-08       Impact factor: 12.449

7.  A vicious cycle of β amyloid-dependent neuronal hyperactivation.

Authors:  Benedikt Zott; Manuel M Simon; Wei Hong; Felix Unger; Hsing-Jung Chen-Engerer; Matthew P Frosch; Bert Sakmann; Dominic M Walsh; Arthur Konnerth
Journal:  Science       Date:  2019-08-09       Impact factor: 47.728

8.  Intracellular Ca2+ stores control in vivo neuronal hyperactivity in a mouse model of Alzheimer's disease.

Authors:  Chommanad Lerdkrai; Nithi Asavapanumas; Bianca Brawek; Yury Kovalchuk; Nima Mojtahedi; Maria Olmedillas Del Moral; Olga Garaschuk
Journal:  Proc Natl Acad Sci U S A       Date:  2018-01-22       Impact factor: 11.205

9.  β-Secretase BACE1 Is Required for Normal Cochlear Function.

Authors:  Marlen Dierich; Stephanie Hartmann; Nadine Dietrich; Philip Moeser; Franziska Brede; Lejo Johnson Chacko; Konstantin Tziridis; Achim Schilling; Patrick Krauss; Sabine Hessler; Sandra Karch; Anneliese Schrott-Fischer; Michael Blumer; Carmen Birchmeier; Dominik Oliver; Tobias Moser; Holger Schulze; Christian Alzheimer; Michael G Leitner; Tobias Huth
Journal:  J Neurosci       Date:  2019-09-16       Impact factor: 6.167

Review 10.  Amyloid-β: a potential link between epilepsy and cognitive decline.

Authors:  Michele Romoli; Arjune Sen; Lucilla Parnetti; Paolo Calabresi; Cinzia Costa
Journal:  Nat Rev Neurol       Date:  2021-06-11       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.